arrow
D

David S. Moura

Universidad Autonoma de Madrid
H指数:19
被引数:1,488

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

NAB2::STAT6 Fusion Proteins Drive Nuclear Condensate Formation and Transcriptional Reprogramming in Solitary Fibrous Tumors

NAB2::STAT6融合蛋白驱动孤立性纤维瘤中核凝聚体的形成和转录重编程

2026-05-220
OAAI
Spatial immunoprofiling of retroperitoneal leiomyosarcomas reveals intratumoral heterogeneity in immune cell infiltration, checkpoint molecule expression, and tertiary lymphoid structures

腹膜后平滑肌肉瘤的空间免疫组化分析揭示了肿瘤内部在免疫细胞浸润、检查点分子表达和三级淋巴结构方面的异质性。

2025-10-130
OAAI
Genomics-led approach to drug testing in models of undifferentiated pleomorphic sarcoma

基因组学导向的方法在未分化多形性肉瘤模型中的药物测试

2025-05-260
OAAI
Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial
CANCER
IF5.1
2024-11-141
PRE
Exploratory analysis of immunomodulatory factors identifies L1CAM as a prognostic marker in alveolar soft-part sarcoma
2024-11-040
OAAI
Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
2024-09-160
PRE
IMMUNOSARC II master trial (phase II of sunitinib and nivolumab): Results from the clear cell sarcoma (CCS) cohort: A GEIS, ISG, and UCL study

IMMUNOSARC II主试验(舒尼替尼和纳武利尤单抗的II期):透明细胞肉瘤(CCS)队列的结果:一项GEIS、ISG和UCL研究

2024-09-010
PRE
Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor
2024-09-010
PRE
HMGA1 regulates trabectedin sensitivity in advanced soft-tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study
2024-05-172
OAAI
Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma
2024-01-271
OAAI
Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain
2024-01-090
OAAI
Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry
2023-12-016
OAAI